Latest Insider Transactions at Verona Pharma PLC (VRNA)
This section provides a real-time view of insider transactions for Verona Pharma PLC (VRNA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Verona Pharma plc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Verona Pharma plc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 07
2025
|
Andrew Fisher General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,349,887
-100.0%
|
-
|
|
Oct 07
2025
|
Andrew Fisher General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
931,984
+50.0%
|
-
|
|
Oct 07
2025
|
Anders Ullman Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
430,856
-100.0%
|
-
|
|
Oct 07
2025
|
Anders Ullman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
72,000
+50.0%
|
-
|
|
Oct 07
2025
|
Michael Austwick Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
84,712
-100.0%
|
-
|
|
Oct 07
2025
|
Michael Austwick Director |
BUY
Exercise of conversion of derivative security
|
Direct |
72,000
+50.0%
|
-
|
|
Oct 07
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,550,248
-100.0%
|
-
|
|
Oct 07
2025
|
Mark W Hahn Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,285,280
+50.0%
|
-
|
|
Oct 07
2025
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,564,852
-100.0%
|
-
|
|
Oct 07
2025
|
Kathleen A. Rickard Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,131,984
+50.0%
|
-
|
|
Oct 07
2025
|
David Zaccardelli President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,461,424
-100.0%
|
-
|
|
Oct 07
2025
|
David Zaccardelli President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,285,280
+50.0%
|
-
|
|
Oct 07
2025
|
Lisa Deschamps Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
156,856
-100.0%
|
-
|
|
Oct 07
2025
|
Lisa Deschamps Director |
BUY
Exercise of conversion of derivative security
|
Direct |
72,000
+50.0%
|
-
|
|
Oct 07
2025
|
Vikas Sinha Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
166,112
-100.0%
|
-
|
|
Oct 07
2025
|
Vikas Sinha Director |
BUY
Exercise of conversion of derivative security
|
Direct |
72,000
+50.0%
|
-
|
|
Oct 07
2025
|
Mahendra Shah Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
165,472
-100.0%
|
-
|
|
Oct 07
2025
|
Mahendra Shah Director |
BUY
Exercise of conversion of derivative security
|
Direct |
72,000
+50.0%
|
-
|
|
Oct 07
2025
|
Christina Ackermann Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
136,072
-100.0%
|
-
|
|
Oct 07
2025
|
Christina Ackermann Director |
BUY
Exercise of conversion of derivative security
|
Direct |
72,000
+50.0%
|
-
|
|
Oct 07
2025
|
Kenneth Cunningham Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
151,776
-100.0%
|
-
|
|
Oct 07
2025
|
Kenneth Cunningham Director |
BUY
Exercise of conversion of derivative security
|
Direct |
72,000
+50.0%
|
-
|
|
Oct 07
2025
|
James Aloysius Brady Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
95,176
-100.0%
|
-
|
|
Oct 07
2025
|
James Aloysius Brady Director |
BUY
Exercise of conversion of derivative security
|
Direct |
72,000
+50.0%
|
-
|
|
Oct 07
2025
|
Martin Edwards Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
229,992
-100.0%
|
-
|
|
Oct 07
2025
|
Martin Edwards Director |
BUY
Exercise of conversion of derivative security
|
Direct |
72,000
+50.0%
|
-
|
|
Oct 07
2025
|
David R Ebsworth Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
617,600
-100.0%
|
-
|
|
Oct 07
2025
|
David R Ebsworth Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
952,499
-100.0%
|
-
|
|
Oct 07
2025
|
David R Ebsworth Director |
BUY
Exercise of conversion of derivative security
|
Direct |
72,000
+50.0%
|
-
|
|
Aug 29
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
1,200,000
-9.63%
|
-
|
|
Aug 29
2025
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Bona fide gift
|
Direct |
189,600
-7.27%
|
-
|
|
Aug 29
2025
|
David Zaccardelli President and CEO |
SELL
Bona fide gift
|
Direct |
1,200,000
-8.97%
|
-
|
|
Aug 01
2025
|
Andrew Fisher General Counsel |
SELL
Open market or private sale
|
Direct |
9,584
-2.24%
|
$124,592
$13.14 P/Share
|
|
Aug 01
2025
|
Andrew Fisher General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,888
+4.66%
|
-
|
|
Aug 01
2025
|
Lisa Deschamps Director |
SELL
Open market or private sale
|
Direct |
9,464
-10.03%
|
$123,032
$13.14 P/Share
|
|
Aug 01
2025
|
Lisa Deschamps Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+20.28%
|
-
|
|
Aug 01
2025
|
Kenneth Cunningham Director |
SELL
Open market or private sale
|
Direct |
10,808
-11.93%
|
$140,504
$13.14 P/Share
|
|
Aug 01
2025
|
Kenneth Cunningham Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+20.95%
|
-
|
|
Aug 01
2025
|
Michael Austwick Director |
SELL
Open market or private sale
|
Direct |
11,288
-47.03%
|
$146,744
$13.14 P/Share
|
|
Aug 01
2025
|
Michael Austwick Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+50.0%
|
-
|
|
Aug 01
2025
|
Christina Ackermann Director |
SELL
Open market or private sale
|
Direct |
1,808
-2.74%
|
$23,504
$13.14 P/Share
|
|
Aug 01
2025
|
Christina Ackermann Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+26.7%
|
-
|
|
Aug 01
2025
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
58,336
-2.19%
|
$758,368
$13.14 P/Share
|
|
Aug 01
2025
|
Kathleen A. Rickard Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
70,888
+2.59%
|
-
|
|
Aug 01
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
208,912
-1.65%
|
$2,715,856
$13.14 P/Share
|
|
Aug 01
2025
|
Mark W Hahn Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
255,696
+1.98%
|
-
|
|
Aug 01
2025
|
Martin Edwards Director |
SELL
Open market or private sale
|
Direct |
10,808
-6.4%
|
$140,504
$13.14 P/Share
|
|
Aug 01
2025
|
Martin Edwards Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+12.45%
|
-
|
|
Aug 01
2025
|
David R Ebsworth Director |
SELL
Open market or private sale
|
Direct |
1,904
-0.22%
|
$24,752
$13.14 P/Share
|
|
Aug 01
2025
|
David R Ebsworth Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+2.65%
|
-
|